Physician profile

Paul E Kudelko

Cardiovascular Disease · Hendersonville, TN

NPI 1225027014

$155,631.11

in general payments reported to CMS, 2019-2025

37 companies · $69K in 2025

The $69K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$129,659.19
Travel and Lodging$14,068.67
Food and Beverage$6,377.05
Education$32.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $146,806.28 2023-2025 Wegovy, Ozempic, Rybelsus
Janssen Pharmaceuticals, INC $1,755.71 2019-2023 Xarelto
Amgen INC. $1,327.43 2019-2024 Repatha
Inari Medical, INC. $885.86 2019-2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Pfizer INC. $439.19 2019-2025
Shockwave Medical, INC $438.06 2021-2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Abbott Laboratories $421.03 2022-2023 Thoratec Heartmate 3 Lvas Implant Kit
Novartis Pharmaceuticals Corporation $408.68 2019-2024
Boston Scientific Corporation $404.60 2019-2025 Watchman Flx, Watchman Access System
E.R. Squibb & Sons, L.L.C. $379.91 2019-2025 Camzyos, Eliquis
Astrazeneca Pharmaceuticals LP $294.90 2019-2023 Brilinta
Boehringer Ingelheim Pharmaceuticals, INC. $275.49 2021-2025 Jardiance
Actelion Pharmaceuticals US, INC. $227.67 2021-2024 Uptravi, Opsumit
Bayer Healthcare Pharmaceuticals INC. $226.54 2021-2025
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $165.21 2019-2025 Lifevest
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Inquis Medical, INC. $158.03 2025 Aventus
Merck Sharp & Dohme LLC $129.12 2023-2025 Verquvo, Winrevair
Kiniksa Pharmaceuticals, LTD. $118.15 2021-2023 Arcalyst
Baxter Healthcare $94.28 2024 Hillrom - Carnation Ambulatory Monitor
Amarin Pharma, INC. $83.78 2019-2021
Esperion Therapeutics, INC. $79.61 2020-2022
Kiniksa Pharmaceuticals International, Plc $53.85 2024 Arcalyst
Astellas Pharma US INC $49.48 2019-2021
Sanofi-Aventis U.S. LLC $47.61 2021-2024
Lilly USA, LLC $45.46 2022
Lundbeck LLC $41.37 2019-2021
Abiomed $41.30 2024 Impella
Regeneron Healthcare Solutions, INC. $39.68 2020-2021
Portola Pharmaceuticals, LLC $28.82 2019
Hologic Sales and Service, LLC $25.78 2025 Aptima
Acist Medical Systems, INC. $23.96 2023
Alnylam Pharmaceuticals INC. $23.84 2024 Onpattro
Surmodics, INC. $23.01 2023 Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Microcatheter, 014, 65cm, Straight, Sublime Microcatheter, 014, 65cm, Angle
Celonova Biosciences, INC. $20.41 2019
Cardiac Dimensions, INC. $19.11 2024
Lexicon Pharmaceuticals, INC. $18.96 2023 Inpefa
Cashflow Solutions, LLC $8.94 2024 Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White, Pcd-51 731a (US) - White

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Paul E Kudelko

$155,631.11

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk INC
Context
The $69K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/55452/paul-e-kudelko

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.